Pharmacogenetic Drug Use and Adverse Reaction Correlations in a Population Sample

2149 adults participated in a telecommunication-based cross-sectional survey assessing pharmacogenetic drug use. The study, led by Nina D. Anfinogenova and last updated in April 2026, found nearly 70% of respondents were taking pharmacotherapy and 28% had clinically significant drug-gene interactions. Carriership of loss-of-function variants in genes like CYP2C19 and UGT1A1 was associated with increased susceptibility to adverse drug reactions.

Use Cases

• Analyzing correlations between pharmacogenetic drug intake and self-reported susceptibility to adverse drug reactions based on survey responses.
• Studying the association between specific genetic variants (e.g., CYP2C19*2/*17, UGT1A1 7TA/7TA) and drug response in a genotyped subgroup.
• Estimating the population prevalence of actionable drug-gene interactions involving CYP2C19, CYP2C9, CYP2D6, and UGT1A1.

Strengths

• Includes a substantial population sample of 2149 respondents for survey analysis.
• Contains a genotyped subgroup (n=83) for direct genetic correlation analysis.
• Provides specific statistical results, such as the correlation (r=0.3317, p=0.003012) between CYP2C19*2/*17 carriership and ADR susceptibility.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the primary data tables is unknown, which may limit suitability assessment.
• The genotyped subgroup is relatively small (83 individuals) compared to the full survey sample.

Provenance

Source

Nina D. Anfinogenova via figshare.

Collection Method

Data was gathered via an online survey initiated by SMS invitations sent to random adults.

Freshness

Last updated 2026-04-21 08:13:53; freshness should be verified.